TD Cowen raised the firm’s price target on Pacific Biosciences to $17 from $15 and keeps an Outperform rating on the shares. The analyst said the 1st quarter of the Revio launch hit on most accounts in that it had a 13% revenue beat, strong placements and orders, excellent in-field performance and a modest sales guidance raise.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PACB:
- Pacific Biosciences reports Q1 EPS (36c), consensus (33c)
- PacBio Announces Record Revenue in First Quarter 2023
- PACB Upcoming Earnings Report: What to Expect?
- Pacific Biosciences upgraded to Outperform from Market Perform at TD Cowen
- Pacific Biosciences announces new workflows developed with Corteva